These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23651074)

  • 41. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
    Ychou M; Boige V; Pignon JP; Conroy T; Bouché O; Lebreton G; Ducourtieux M; Bedenne L; Fabre JM; Saint-Aubert B; Genève J; Lasser P; Rougier P
    J Clin Oncol; 2011 May; 29(13):1715-21. PubMed ID: 21444866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
    Leonard GD; Zhuang SH; Grem JL
    J Clin Oncol; 2002 Oct; 20(19):4124-5; author reply 4125-6. PubMed ID: 12351613
    [No Abstract]   [Full Text] [Related]  

  • 43. Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
    Messager M; Neofytou K; Chaudry MA; Allum WH
    Eur J Surg Oncol; 2015 Oct; 41(10):1316-23. PubMed ID: 26166786
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma.
    Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M
    Anticancer Res; 2015 Jan; 35(1):419-25. PubMed ID: 25550582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone.
    Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB
    Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
    Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
    Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
    Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A
    Br J Cancer; 1995 Mar; 71(3):583-6. PubMed ID: 7880742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
    Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI
    J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas.
    Karapetis CS; Cheong KA; Yip D; Strickland AH; Steer C; Marx G; Yip S; Chrystal K; Harper PG
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):298-305. PubMed ID: 21114780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
    J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Okines AF; Langley RE; Thompson LC; Stenning SP; Stevenson L; Falk S; Seymour M; Coxon F; Middleton GW; Smith D; Evans L; Slater S; Waters J; Ford D; Hall M; Iveson TJ; Petty RD; Plummer C; Allum WH; Blazeby JM; Griffin M; Cunningham D
    Ann Oncol; 2013 Mar; 24(3):702-9. PubMed ID: 23108952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
    Haag GM; Byl A; Jäger D; Berger AK
    Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peri-operative chemotherapy in patients with oesophageal and gastro-oesophageal junction cancer - three years of experience.
    Pechačová Z; Zemanová M; Haruštiak T; Vítek P; Fencl P
    Prague Med Rep; 2013; 114(2):57-71. PubMed ID: 23777797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
    Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy.
    Makary MA; Kiernan PD; Sheridan MJ; Tonnesen G; Hetrick V; Vaughan B; Graling P; Elster E
    Am Surg; 2003 Aug; 69(8):693-700; discussion 700-2. PubMed ID: 12953828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Okines AF; Ashley S
    N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.